Drug intelligence / Profile preview

anti-oxLDL IgM antibody

Development stage
Preclinical
Modality
IgM Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous, Intramuscular, Subcutaneous
01

Overview

Anti-oxLDL IgM antibody refers to an immunoglobulin M (IgM) class monoclonal or polyclonal antibody that specifically recognizes and binds to oxidized low-density lipoprotein (oxLDL). Oxidized LDL is a modified form of LDL cholesterol implicated in the pathogenesis of atherosclerosis and cardiovascular disease. The mechanism of action for these antibodies involves binding to oxidation-specific epitopes on oxLDL particles, thereby neutralizing their pro-inflammatory effects and promoting their clearance from circulation. This can inhibit macrophage chemotaxis and inflammation within arterial plaques, potentially stabilizing plaques and reducing the risk of rupture or thrombosis[1][2][5]. Experimental studies have shown that passive immunization with natural or engineered anti-oxLDL IgM antibodies (such as Moab A7S8) can reduce atherosclerotic plaque development in animal models[5]. In humans, higher levels of endogenous anti-oxLDL IgM are associated with protection against coronary artery disease progression[2][8]. These antibodies are being investigated primarily for secondary prevention in cardiovascular diseases such as coronary artery disease and myocardial infarction.

Other names
anti-oxidized LDL IgM antibodyantioxLDL IgMHOCl-oxLDL-specific IgM monoclonal antibodyMoab A7S8
02

Targets

Oxidized low-density lipoprotein neoepitopes

Beyond the preview

Go deeper on anti-oxLDL IgM antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-oxLDL IgM antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call